AstraZeneca Reports Positive Phase III Data for Subcutaneous Lupus Therapy
WILMINGTON, DE — AstraZeneca announced positive interim results from its Phase III TULIP-SC trial showing that subcutaneous administration of SAPHNELO (anifrolumab) significantly reduced disease activity in patients with systemic lupus …
AstraZeneca Reports Positive Phase III Data for Subcutaneous Lupus Therapy Read More